Cell-autonomous GP130 activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment
C. Sternberg, T. Limberger, M. Raigel, K. Trachtova, M. Schlederer, D. Lindner, P. Kodajova, J. Yang, R. Ziegler, H. A. Neubauer, S. Dey, T. Redmer, S. Stoiber, V. Hejret, B. Tichy, , L. Kenner
This study shows that activating GP130 in prostate epithelial cells suppresses tumor growth through senescence and immune activation, suggesting a new therapeutic approach.
bioRxiv · Feb 11, 2024 · PreprintCancer Biology